Showing 828 results
-
Media Release /New post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently…
-
Media Release /Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment EAST HANOVER, N.J., April 12, 2021…
-
Media Release /The STEP (Solutions to Empower Patients) ProgramTM supports the development of creative new approaches to reimagine care Recipients will launch variety of initiatives to help caregivers of people…
-
Media Release /With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
-
Media Release /The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval…
-
Media Release /Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently…
-
Media Release /PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24…
-
Media Release /PROS is a spectrum of at least 13 rare conditions driven by mutations in the PIK3CA gene, typically associated with tissue overgrowth, vascular malformations, and neurological disorders New…
-
Media Release /Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
-
Media Release /Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
